Moderna said Wednesday that its bivalent COVID-19 vaccine booster candidate elicited a superior antibody response against the omicron variant of SARS-CoV-2 compared with the original vaccine.
The bivalent vaccine, also called mRNA-1273.214, contains the original vaccine and a new vaccine targeting the omicron variant.
It has the potential to provide broad immunity against new variants that may develop, the company said in a press release.
Moderna said a 50 µg dose of the new booster was “generally well-tolerated, with side effects comparable to” a 50 µg booster dose of the original